The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford,… Read More
Oxford, UK – 1 June, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that Dr. Roch Doliveux will become Non-Executive Chairman of the Group with effect from 24 June 2020. As announced on 18 March 2020,… Read More
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford,… Read More
London, UK – 22 May 2020: Oxford Biomedica plc (“Oxford Biomedica”, “the Company” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, gives notice that copies of the 2019 Annual report and accounts and the Notice of Annual General Meeting (“AGM”) have been sent to shareholders. These… Read More
Oxford, UK – 13 May, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today the successful outcome of their recent UK Medicines & Healthcare products Regulatory Agency (MHRA) inspection, resulting in the issue of a Certificate of GMP compliance… Read More
Oxford Biomedica plcPreliminary results for the year ended 31 December 2019 Building the Group for future growth Oxford, UK – 6 May 2020: Oxford Biomedica plc (LSE: Oxford Biomedica), (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces its preliminary results for the… Read More
Oxford, UK – 22nd April, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes the announcement from Novartis that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kymriah® (tisagenlecleucel), for an investigational… Read More
Full Year Results to be Published on 6th May 2020 Oxford, UK – 16th April, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announces today that, following guidance from the Financial Reporting Council (FRC) and Financial Conduct Authority (FCA)… Read More
Consortium led by Jenner Institute, University of Oxford Fast-tracked clinical trial of ChAdOx1 nCOV-19 vaccine candidate starts this month Oxford, UK – 8th April, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today it has joined… Read More
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford,… Read More
Business Update Oxford, UK – 18 March 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announces today an unaudited trading and business update to 31 December 2019 and post period end review. The Group expects to announce its preliminary results… Read More
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Oxford,… Read More